...
首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >Cellular mechanisms promoting cachexia and how they are opposed by sirtuins
【24h】

Cellular mechanisms promoting cachexia and how they are opposed by sirtuins

机译:促进恶棍的细胞机制以及他们是如何由SIRTUIN反对的

获取原文
获取原文并翻译 | 示例
           

摘要

Many chronic diseases are associated with unintentional loss of body weight, which is termed "cachexia". Cachexia is a complex multifactorial syndrome associated with the underlying primary disease, and characterized by loss of skeletal muscle with or without loss of fat tissue. Patients with cachexia face dire symptoms like dyspnea, fatigue, edema, exercise intolerance, and low responsiveness to medical therapy, which worsen quality of life. Because cachexia is not a stand-alone disorder, treating primary disease - such as cancer - takes precedence for the physician, and it remains mostly a neglected illness. Existing clinical trials have demonstrated limited success mostly because of their monotherapeutic approach and late detection of the syndrome. To conquer cachexia, it is essential to identify as many molecular targets as possible using the latest technologies we have at our disposal. In this review, we have discussed different aspects of cachexia, which include various disease settings, active molecular pathways, and recent novel advances made in this field to understand consequences of this illness. We also discuss roles of the sirtuins, the NAD(+)-dependent lysine deacetylases, microRNAs, certain dietary options, and epigenetic drugs as potential approaches, which can be used to tackle cachexia as early as possible in its course.
机译:许多慢性疾病与无意的体重丧失有关,其被称为“恶毒思症”。 Cachexia是一种复杂的多因素综合征,其与潜在的主要疾病相关,并通过损失或不损失脂肪组织的损失而表征。患者患者患有呼吸困难症状,如呼吸困难,疲劳,水肿,运动不耐受,以及对医疗治疗的反应性低,这使得生活质量恶化。因为恶毒症不是单独的单独疾病,所以治疗原发性疾病 - 例如癌症 - 优先于医生,并且它仍然是被忽视的疾病。由于其单一视觉方法和综合征的晚期检测,现有的临床试验主要取得有限的成功。为了征服恶棍,必须使用我们所提供的最新技术尽可能多地识别尽可能多的分子目标。在本综述中,我们讨论了疾病的不同方面,其中包括各种疾病环境,活跃的分子途径和在该领域的最近进行了最近的新推进,以了解这种疾病的后果。我们还讨论了SIRTUINS的角色,NAD(+)依赖性赖氨酸脱乙酰酶,MicroRNA,某些膳食选择和表观遗传药物作为潜在方法,可用于尽早在其过程中尽早解决恶毒糖尿病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号